Abstract This study was performed out to establish the antinociceptive, anti-inflammatory, and antipyretic properties of an aqueous extract of Dicranopteris linearis leaves in experimental animals. The antinociceptive activity was measured using the abdominal constriction, hot plate, and formalin tests. The anti-inflammatory and antipyretic activities were measured using the carrageenaninduced paw edema and brewer's yeast-induced pyrexia tests, respectively. The extract, obtained after 72 h soaking of the air-dried leaves in distilled water and then prepared in the doses of 13.2, 66.0, 132.0, and 660.0 mg/kg, was administered subcutaneously 30 min before subjecting the animals to the assays mentioned above. Generally, the extract, at all doses used, was found to have significant (P \ 0.05) concentration-independent antinociceptive, anti-inflammatory, and anti-pyretic activity. In conclusion, the aqueous extract of D. linearis has antinociceptive, antiinflammatory, and antipyretic activity, supporting previous claims of its traditional use by the Malays to treat various ailments, particularly fever.
Introduction
Many plants, especially the seedless vascular pteridophytes, are generally much neglected as far as their economic value is concerned, yet the ethnobotanical uses of this unique group are enormous. Pteridophytes occupy a position between the lower non-seed-bearing and higher seed-bearing plants. Many species of ferns and fern allies are of enormous economic utility with the most important being their medicinal, aesthetic, and food value [1] . Dicranopteris linearis (L.), locally known to the Malays as ''Resam'', is a plant that belongs to the family Gleicheniaceae [2, 3] . D. linearis is common in secondary forests and grows well on poor clay soils. It belongs to a family of ferns that is considered somewhat primitive and is among the few branching ferns that can quickly develop into thickets up to 2 m tall, shading out all other plants [4, 5] .
In Malaysia, particularly, the leaves of D. linearis were used in folklore medicine to reduce body temperature and to control fever [2, 6] . The leaves were squeezed in water and the water was then drunk or the wet leaves were applied to the body as poultice. However, on the basis of a literature search, there are few reports of its traditional uses in other parts of the world, with only two reports describing its use to treat external wounds, ulcers, and boils by the people of Papua New Guinea [6] , to get rid of intestinal worms by the people of Indochina [6] , and to treat asthma and women's sterility by the tribes on an Indian mountain [1] . Scientifically, D. linearis has been reported to contain different flavonoids of the flavonol 3-O-glycosides type [7] . Depending on the varieties of fern used, D. linearis contained afzelin, quercitrin, isoquercitrin, astragarin, rutin, kaempferol 3-O-(4-O-p-coumaroyl-3-O-alpha-Lrhamnopyranosyl)-alpha-L-rhamnopyranosyl-(1?6)-beta-D -glucopyranoside, and (6S,13S)-6-[6-O-acetyl-beta-D-glucopyranosyl-(1?4)-alpha-L-rhamnopyranosyloxy]-13-[alpha-Lrhamnopyranosyl-(1?4)-beta-D-fucopyranosyloxy]cleroda-3, 14-diene. Other than these, reports involving D. linearis have focused on rare earth elements [8, 9] and allergenicity [10] .
On the basis of the traditional claim that D. linearis is an antipyretic agent, as described above, and the lack of scientific studies to establish its potential pharmacological properties, the objective of this study was to evaluate the antinociceptive, anti-inflammatory, and antipyretic properties of an aqueous extract of D. linearis leaves.
Materials and methods

Plant material
The leaves of D. linearis were collected in June-July 2005 from its natural habitat in Shah Alam, Selangor, Malaysia, and identified by Mr Shamsul Khamis, a botanist at the Institute of Bioscience (IBS; Universiti Putra Malaysia (UPM), Serdang, Selangor, Malaysia). A voucher specimen (SK 855/05) was deposited at the Herbarium of the Laboratory of Natural Products, IBS, UPM, Serdang, Selangor, Malaysia.
Phytochemical screening of the D. linearis leaves Phytochemical screening of the D. linearis leaves was carried out in accordance with standard screening tests and conventional protocols [11] .
Preparation of an aqueous extract of D. linearis (AEDL)
The leaves of D. linearis were washed and rinsed with water to remove all dirt and unwanted particles and then air-dried for 1-2 weeks at room temperature (27 ± 2°C). The dried leaves were then sliced into small pieces, weighed (10 g), and added to distilled water (dH 2 O) in the ratio 1:20 (w/v). This mixture was then left for 72 h and the supernatant was collected and filtered using a Whatman no. 1 filter paper. The remaining plant residue was kept in an oven. The supernatant obtained, labeled AEDL and considered as stock solution with 100% concentration/strength, was prepared at concentrations/strengths of 10 and 50%, by diluting the stock solution with dH 2 O, for pharmacological studies. Approximately 30 mL of the supernatant was also subjected to freeze-drying (Virtis, Gardiner, NY, USA) and yielded 0.397 g of crude dried AEDL (yield 26.47%). On the basis of the amount of crude dried AEDL obtained, it was estimated that the 10, 50, and 100% concentrations of AECC were approximately equivalent to doses of 13.2, 66.0, and 132.0 mg/kg, respectively. Additional doses (660 and 1,320 mg/kg) were prepared later using the freezedried crude AEDL and used with the other doses (13.2, 66.0 and 132.0 mg/kg) in the pharmacological studies.
HPLC profiling of the AEDL HPLC profiling of the AEDL was performed at the Laboratory of Phytomedicine, Forest Research Institute of Malaysia, Kepong, Malaysia. A Waters (Milford, MA, USA) Delta 600 with Waters 600 controller and Waters 2996 photodiode-array detector, equipped with an autosampler, online degasser, and column heater, was used for HPLC analysis. Data were analyzed and processed using the installed Millennium 32 software (Waters). The samples were separated at 27°C on a minibore Phenomenex Luna 5 lm C 18 column, dimensions 250 9 4.60 mm, using a one-step linear gradient. The mobile phase components were (A) 0.1% aqueous orthophosphoric acid and (B) acetonitrile, and the gradient program was: 0-12 min, 0-15% B; 12-22 min, 15-25% B; 22-35 min, 25-15% B. The flow rate was 1,000 lL/min. The HPLC was monitored at 200, 254, and 330 nm.
Preparation of drugs
Solutions of acetylsalicylic acid (ASA; Bayer, Singapore; 100 mg/kg) and morphine (Sigma, Germany; 5 mg/kg), used for comparison purposes, were prepared in dH 2 O.
Experimental animals
Male BALB/c mice (25-30 g; 5-7 weeks) and SpragueDawley rats (180-200 g; 8-10 weeks), obtained from the Animal Source Unit, Faculty of Veterinary Medicine, Universiti Putra (UPM), Serdang, Selangor, Malaysia, were used in this study. All animals were kept at room temperature (27 ± 2°C; 70-80% humidity; 12 h light/dark cycle) in the Animal Holding Unit, Faculty of Medical and Health Sciences, UPM, for at least 48 h before use. Food and water were supplied ad libitum up to the beginning of the experiments. At all times the rats were cared for in accordance with current UPM principles and guidelines for the care of laboratory animals and the UPM ethical guidelines for investigation of experimental pain in conscious animals as adopted from Zimmermann [12] .
The mice were divided into ten groups of seven mice each (n = 7) and received (sc) dH 2 O, ASA (100 mg/kg), or AEDL (13.2, 66.0, or 132.0 mg/kg) 30 min before subjection to the abdominal constriction or hot-plate tests. Rats were divided into 11 groups of five rats each (n = 5). The first six groups were used in the formalin test and received (sc) dH 2 O, 100 mg/kg ASA, 5 mg/kg morphine or AEDL (13.2, 66.0, or 132.0 mg/kg) 30 min before subjection to the antinociceptive, anti-inflammatory, and antipyretic tests. The second and third groups of five were used in the antiinflammatory and antipyretic studies, and received (sc) dH 2 O, 100 mg/kg ASA or AEDL (13.2, 66.0, or 132.0 mg/ kg) 30 min before subjection to the tests. All test solutions were administered in a volume of 10 mL/kg body weight.
Antinociceptive assay
Abdominal constriction test
The abdominal constriction test described by Koster et al. [13] , with slight modifications, was used to evaluate the chemically-induced peripheral antinociceptive activity of AEDL. Acetic acid (J.T. Baker, Phillipsburg, NJ, USA), prepared as 0.6% (v/v) solution in dH 2 O and used to induce pain in the peritoneal cavity of mice, was administered intraperitoneally (ip) in a volume of 10 mL/kg 30 min after sc administration of dH 2 O, ASA, or AEDL. The abdominal constriction resulting from injection of acetic acid consists of contraction of the abdominal region and stretching of the hind limbs. The number of abdominal constrictions was counted cumulatively over a period of 25 min, commencing 5 min after administration of the acetic acid. Antinociceptive activity was indicated by reduction in the mean of the number of abdominal constrictions in the test groups compared with the control group.
Hot-plate test
The 50°C hot-plate test described by Wilson et al. [14] , with slight modification, was used to assess the central antinociceptive activity of AEDL against thermally induced pain. This assay is a modification of a classic hotplate test in which the lower intensity is designed to increase the sensitivity of the test to weak analgesic. The temperature of the metal plate (Model 7280, Ugo Basile, Italy) was maintained at 50 ± 0.2°C. Mice were placed on the heated surface, within Plexiglas walls to constrain their locomotion on the plate, and latency to a discomfort reaction (licking of the paws or jumping) was recorded 0, 1, 2, 3, 4, and 5 h after sc administration of dH 2 O, morphine or AEDL. A cut-off time of 20 s was chosen to indicate complete analgesia and to avoid tissue injury. Prolongation of the latency time of the treated groups was statistically compared with values for the control. Control animals were treated with dH 2 O (10 mL/kg; sc) and morphine (5 mg/kg; sc) was used as reference drug [15] .
Formalin test
The formalin test described by Hunskaar et al. [16] was used, but with slight modifications. Pain was induced by injecting 50 ll 5% formalin in the subplantar region of the left hind paw. Rats were given (sc) dH 2 O, ASA, or AEDL 30 min before formalin injection. The rats were individually placed in transparent Plexiglass cage observation chambers. The duration of time the animal spent licking the injected paw, considered as an indicator of pain, was recorded for 30 min after the formalin injection. The early phase of nociception, indicating a neurogenic type of pain response, was measured between 0 and 5 min while the late phase of nociception, indicating an inflammatory type of pain response, was measured 15-30 min after formalin injection. ASA (100 mg/kg; sc) and morphine (5 mg/kg; sc) dissolved in dH 2 O were used as reference drugs.
Anti-inflammatory assay
The carrageenan-induced paw edema test described by Winter et al. [17] was used, with slight modifications. Acute inflammation was produced by subplantar injection of 0.1 mL of a 1% suspension of carrageenan in dH 2 O into the right hind paw of the rats, 30 min after administration (sc) of dH 2 O, ASA, or AEDL. The thickness of the paw was measured with calipers before (BF) and 0, 1, 2, 3, 4, 5, 6, 7 and 8 h after carrageenan (ipl) treatment. The results obtained for the ASA or AEDL-treated groups were compared with those for the dH 2 O-treated group and the difference between the readings was taken as the indicator of edema. ASA (100 mg/kg; sc) dissolved in dH 2 O was used as reference drug.
Antipyretic assay Antipyretic activity of AEDL was measured according to the method described by Adams et al. [18] , but with slight J Nat Med (2008) 
Statistical analysis
Results are presented as mean ± standard error of mean (SEM). One-way ANOVA with the Dunnett post-hoc test was used to analyze and compare the data, with P \ 0.05 as the limit of significance.
Results
Phytochemical screening of the AEDL
Phytochemical screening of the leaves of D. linearis has revealed the presence of flavonoids, saponins, tannins, steroids, and triterpenes, and the absence of alkaloids.
HPLC profiling of the AEDL
The HPLC profile of the AEDL was acquired at three wavelengths, 200, 254, and 330 nm (Fig. 1) . Comparisons with three standard flavonoids, catechin, rutin, and fisetin, were performed at 200 nm, because those standards were best detected at this wavelength (Fig. 2) . Based on wavelength comparison between the major peaks in the AEDL and the standards, the extract was found to contain, at least, rutin (peak with retention time (t R ) of 14.415 min). Interestingly, the AEDL bioactive compounds were best separated at 200 nm as indicated by an increase in the number of peaks detected.
Pharmacological studies of the AEDL Based on our observations, the 1320.0 mg/kg AEDL was lethal to all the animals tested within 48 h of the end of the experiments. These data were, therefore, not included in the figures discussed in the following section. Figure 3 shows the antinociceptive profile of AEDL assessed using the acetic acid-induced abdominal constriction test in mice. The extract, at all doses used, had significant (P \ 0.05) antinociceptive activity, with dosedependent activity observed only in the range 66.0-660 mg/kg. The effectiveness of 13.2 and 66.0 mg/kg AEDL was equal to that of 100 mg/kg ASA. Interestingly, increasing the dose of the extract to 132.0 and then to 660 mg/kg was found to significantly (P \ 0.05) enhance the AEDL antinociceptive activity with the latter dose causing complete inhibition of abdominal constriction. Figure 4 shows the antinociceptive profile of AEDL assessed using the hot-plate test in mice. The AEDL, at all doses used, had dose-independent antinociceptive activity (P \ 0.05) that lasted until the end of the experiment. Interestingly, all doses of the AEDL had antinociceptive activity 30 min after administration, which is better than morphine, which had activity 60 min after its administration. However, except after an interval of 1 h, the activity of 660.0 mg/kg AEDL was not significantly (P \ 0.05) from that of 132.0 mg/kg AEDL. Figure 5 shows the antinociceptive profile of AEDL assessed using the formalin test in rats. Although significant (P \ 0.05) antinociceptive activity can be seen in both phases of formalin-induced nociception, the activity is dose-dependent only in the late phase (between 66.0 and 660 mg/kg). Figure 6 shows the anti-inflammatory profile of AEDL assessed using the carrageenan-induced paw edema test in rats. It is noteworthy that the anti-inflammatory activity of AEDL was also observed to be dose-independent, with the lowest dose of the extract having no significant activity whereas the highest dose of the extract had significant (P \ 0.05) activity only after an interval of 3 h. The 66.0 and 660.0 mg/kg AEDL had significant (P \ 0.05) antiinflammatory activity 1 h after their administration, with the former having a greater effect. Activity lasted for the next 2-6 h before completely vanishing. Figure 7 shows the antipyretic profile of AEDL assessed using BY-induced pyrexia in rats. The extract was found to have significant (P \ 0.05) dose-independent antipyretic activity, with the 13.2 and 66.0 mg/kg AEDL having equally effective activity for the first 6 h before their activity disappeared for the last 2 h of the experiments. The 132.0 mg/kg AEDL was found to cause a remarkable decrease in the rat's body temperature only 1 h after its administration compared to the other three doses of AEDL. Furthermore, all doses of AEDL had this activity 1 h after their administration, which disappeared completely during the last 2 h of the experiment. Interestingly, the 660.0 mg/kg AEDL caused a significant (P \ 0.05) decrease in the rectal temperature to the normal rectal temperature. The extract alone was found to cause insignificant changes in the rat's normal rectal temperature.
Discussion
This study was conducted to establish the potential pharmacological properties of AEDL based on claims of its use in traditional medicine, as reported earlier [2, 6] . The AEDL was found to have antinociceptive activity when assessed using the abdominal constriction, hot plate, and formalin tests. This activity, which was concentrationindependent, may indicate the involvement of peripheral and central antinociceptive mechanisms. Furthermore, the results obtained also showed that the AEDL is effective in blocking the nociceptive effect induced by the chemical stimulus in the writhing test and by the thermal stimulus in the hot-plate test. The extract is also believed to inhibit nociceptive activity by direct action on the nociceptor in the early phase or by inhibiting the release of inflammatory mediators in the late phase, as observed in the formalin test. The abdominal constriction test, which is very sensitive in the sense that it is able to detect the pain-relieving effect of compounds and dose levels that may be inactive in the hot-plate test [19] , is thought to involve stimulation of the peripheral receptor system and is attributed, at least in part, to the local peritoneal receptors found at the surface of the cells lining the peritoneal cavity [20] . The abdominal constrictions observed in this assay are because of irritation of the peritoneal cavity caused by administration of the acetic acid [21] . Prolonged irritation leads to an increase in the levels of peritoneal fluid prostaglandins, for example PGE 2 and PGF 2a . The increase in prostaglandin levels within the peritoneal cavity then enhances inflammatory pain by increasing capillary permeability [22] . However, the AEDL antinociceptive activity observed with this assay did not indicate whether the activity was specifically due to peripheral and/or central activity [23] . Thus, it was necessary to use the hot plate and formalin assays to further elucidate on the AEDL antinociceptive activity before a final conclusion could be made on the actual mechanism involved.
The hot-plate test, which is used to indicate the involvement of the central antinociceptive mechanism, is thought to involve the spinal reflex [24] . The hot-plate test measures the complex response to a non-inflammatory, acute nociceptive input and is one of the models normally used for studying central antinociceptive activity. It is well known that centrally acting drugs, for example morphine, have this activity in both types of assay [25] while peripherally acting drugs, for example ASA, have been reported to exhibit analgesic activity in the writhing test only [26] . The significant activity of the latter in the writhing test only could be associated with its ability to directly inhibit prostaglandin action [22, 27] or indirectly inhibit prostaglandin synthesis by inhibition of cyclo-oxygenase (COX) activity [28] . Significant activity in the hotplate test indicates involvement of central antinociceptive mechanism.
According to Heapy et al. [29] injection of formalin causes an immediate and intense increase in the spontaneous activity of afferent C fibers and evokes distinct quantifiable behavior indicative of pain, i.e. licking of the injected paw. The formalin test, which is commonly used to study the non-anti-inflammatory, antinociceptive properties of drugs [30] , has been known to produce a distinct biphasic nociceptive response. According to Malmberg and Yaksh [31] , the initial acute response (early phase) can be seen immediately after formalin injection and continues for 5 min (0-5 min), followed by a quiescent period and then a prolonged response (late phase), characterized by a return to high levels of nociception, between 20 and 60 min after injection. Both phases have different properties and are very useful tools, not only for assessing the potency of analgesic agents, but also for elucidating the mechanisms of pain and analgesia. It has been suggested that the early phase is caused by a direct effect of formalin on nociceptors whereas the late phase is a tonic response in which inflammatory processes are involved and neurons in the dorsal horns of the spinal cord are activated [32] . In fact, there is no obvious inflammatory state in the injected paw of the animal during the first 5 to 10 min after the formalin injection. In addition, centrally acting drugs, for example morphine, have been proven to inhibit both phases while peripherally acting drugs, like ASA, inhibit only the late phase of the test [23] . The formalin test can also be used to indicate the potential of analgesic agents to treat chronic pain due to inflammation [33] , in comparison with the abdominal constriction and hot-plate tests, which are indicative of acute pain. On the basis of the results obtained, the AEDL inhibits both phases of formalin-induced nociception indicating the extract's centrally mediated antinociceptive activity [23] and its potential in the treatment of chronic pain [33] . This finding is also in agreement with our study using the hot-plate test, as already mentioned.
The carrageenan-induced rat paw edema test, which measures the ability of a compound to reduce local edema induced in the rat paw by injection of an irritant agent (carrageenan), has been widely used for screening for new anti-inflammatory agents [23, 34] . The edema development depends on the participation of kinins and polymorphonuclear leucocytes with their pro-inflammatory factors, for example prostaglandins [35] . The carrageenan-induced inflammation has also been claimed to involve a biphasic response, generally known as the early and late phases [36, 37] . The early phase, observed within the first 60 min, is attributed to the release of serotonin and histamine [38] while the late phase of edema is because of the release of prostaglandin-like substances [36] . According to Di Rosa et al. [39] the late phase of edema is sensitive to clinically useful steroidal and non-steroidal anti-inflammatory agents [39] . Although in this study only the thickness of the hind paw after intraplantar injection of carrageenan was measured [40, 41] , the results obtained do indicate the presence of edema and significant anti-inflammatory activity in AEDL. This finding has scientifically confirmed the folklore use of D. linearis leaves in the treatment of boils, ulcers, or asthma by the people of Papua New Guinea [6] and India [1] .
The AEDL was also found to have antipyretic activity when assessed using the BY-induced pyrexia test. This finding has scientifically confirmed the traditional Malay practice of using D. linearis leaves in the treatment of pyrexia but refuted the claim it is used to cool body temperature [2, 6] . It is well known that pyretic activity involves stimulation of the region in the hypothalamus that controls body temperature, via prostaglandins synthesized within the central nervous system (CNS) [42] and that the blood-brain barrier (BBB) prevents drug molecules or other chemicals from entering the CNS [43] . The ability to cross the BBB could be one of the factors contributing to the observed antipyretic activity and could also be used to explain the observed central antinociceptive activity of AEDL.
The non-concentration-dependent effect seen in most of the assays may be because of a phenomenon known as the therapeutic window [44] . According to Tripathi [45] some drugs have an unusual feature in which therapeutic effect is exerted only over a narrow range of drug doses or plasma drug concentrations. If the doses are below or above this narrow therapeutic range they have sub-optimum beneficial effects or a decline in effects. On the basis of the additional experiments, increasing the dose of AEDL to 660.0 and then to 1320.0 mg/kg were found to cause physiological disturbance (i.e. lack of movement and excretion of bloodcontaining urine) to the animals followed by their death within 48 h at the higher dose. This finding, which is an indicator of toxicity, suggested that the range of pharmacological effectiveness of AEDL was \660.0 mg/kg. Furthermore, the highest antinociceptive effects observed with the 660.0 mg/kg AEDL when assessed using the abdominal constriction and hot-plate tests could be associated with the extract's ability to affect the central nervous system.
Several chemically active flavonoid type constituents have been isolated from the leaves of D. linearis, as described elsewhere [7] . There are, however, no scientific reports on the pharmacological potential of these compounds. Kim et al. [44] reported that flavonoid type compounds have anti-inflammatory activity and this finding supported our recent observation on the antiinflammatory activity of AEDL. Furthermore, Attaway and Zaborsky [46] claimed that compounds with anti-inflammatory activity could also have antinociceptive activity, which is also in agreement with our findings on the antiinflammatory and antinociceptive activity of AEDL. One mechanism proposed to explain the in-vivo anti-inflammatory activity of flavonoid and flavone derivatives is via modulation of pro-inflammatory gene expression, for example inducible NOS and COX-2 [44, 47] . NOS, COX-2, and their inter-related involvement in the nociceptive mechanism have also been reported [23, 31, [48] [49] [50] [51] and this could be a plausible explanation of the AEDL antinociceptive activity observed.
Finally, we conclude that the AEDL has peripheral and central antinociceptive activity and anti-inflammatory and antipyretic activity, which thus confirms the folklore uses of the plant for treatment of various ailments.
